View in EDS

Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.

Saved in:
Bibliographic Details
Title: Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.
Authors: Borgers JSW; Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., van Wesemael TJ; Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., Gelderman KA; Sanquin Diagnostic Services, Amsterdam, Noord-Holland, Netherlands., Rispens T; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, Noord-Holland, UK., Verdegaal EME; Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., Moes DJAR; Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., Korse CM; Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., Welters MJP; Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands., van der Burg SH; Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands., van Houdt WJ; Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., van Thienen JV; Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., Haanen JBAG; Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands j.haanen@nki.nl.; Department of Medical Oncology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., van der Woude D; Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jun 30; Vol. 12 (6). Date of Electronic Publication: 2024 Jun 30.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2024-009215